Table 2.
Overview of cohort studies in men.
| Average age of men | Number of men | Study duration | LC-MS-MS | Immunoassay | Main result | |
|---|---|---|---|---|---|---|
| Rancho Bernardo study [8] | 66 | 352 | 12 yr | x | (i) E: strong correlation with fractures (ii) T: no correlation with fractures | |
| Dubbo study [9] | >60 | 609 | 16 yr | x | (i) T: no correlation with fractures (ii) E: strong correlation with fractures |
|
| Tromso [10] | 50–84 | 1364 | 8.4 yr | x | T, E, SHBG: no correlation with fractures | |
| Rotterdam study [11] | 67.7 ± 6.8 | 178 | 6.5 yr | x | T, E, SHBG: no correlation with fractures | |
| Framingham study [12] | 71 | 793 | 18 yr | x | (i) E: strong correlation with fractures (ii) T + E: strong correlation with fractures | |
| MrOS study [13] | 75 | 2639 | 3.3 yr | x | E, SHBG: strong correlation with fractures |
E: estrogen; T: testosterone; SHBG: sex hormone binding globulin.